Summary: Med 7 LLC has been granted a US patent for Hempzorb81, a full-spectrum hemp CBD compound, recognized for its clinical benefits in extending deep sleep, reducing inflammatory cytokines, and regulating blood glucose and aiding weight loss in type 2 diabetics. The patent highlights the compound’s improved absorption and rapid onset of action through micelle technology, with reductions in HbA1c levels, weight, and inflammatory markers in clinical studies.
Key Takeaways:
- Patent Details: Med 7 LLC received a US patent for Hempzorb81, a full-spectrum hemp CBD compound, recognized for extending deep sleep and offering several health benefits.
- Clinical Benefits: Hempzorb81 has demonstrated clinical efficacy in reducing inflammatory cytokines, improving sleep quality, and regulating blood glucose and aiding in weight loss in type 2 diabetics.
- Enhanced Absorption: The patented micelle technology is designed to increase Hempzorb81’s absorption and onset of action.
Med 7 LLC, a marketer and distributor of health and wellness products to medical professionals, has been granted a US patent for Hempzorb81—its novel full-spectrum hemp CBD compound—for improving sleep quality by extending the period of time spent in deep sleep, proving clinical benefits in the reduction of inflammatory cytokines, and lowering blood glucose levels and weight loss in type 2 diabetics.
This patent highlights Hempzorb81 as proven to increase intestinal absorption resulting in higher potency and a more rapid onset of action. Med 7 uses micelle technology to increase this absorption and bioavailability.
“Absorption and onset of action have been the Achilles Heel for cannabis-related products,” says Matt Smith, CEO of Med 7, in a release. “CBD and the other cannabinoids have a documented oral bioavailability of 6% and an onset of action between 60 and 90 minutes. Our micellized cannabinoids have a proven oral bioavailability of 85% and an onset of action of 15 minutes.”
Patented Benefits
Also cited in the patent is the effect Hempzorb81 has on improving sleep quality. In Med 7 patients, deep sleep was increased by 54 minutes over placebo with awake time reduced by 18 minutes. Resting heart rate was also improved on those using Hemporb81, demonstrating the overall quality and improvement on sleep.
In the area of pain and inflammation, Med 7-treated patients saw a reduction of circulating levels of tumor necrosis factor alpha and interleukin 6. “This is impressive,” according to David Cooper, PhD, MD, senior author on findings published in Clinics in Medicine, in a release. “Regular consumption of Hempzorb81 has been shown to decrease these inflammatory markers by as much as 25 to 50% or more. Reducing these inflammation markers improved the immune response to viral disease and decreased joint pain.”
Also included in this patent is the data regarding the impact Hempzorb81 has on blood glucose regulation and the management of pain. HbA1c changes were significant in a six-month study in type II diabetics as Med 7-treated patients had an average HbA1c reduction of 1.2 points vervus placebo. Med 7 patients also saw an average of weight loss of 13.7 pounds and over three inches in girth reduction versus placebo.
“We believe that the granting of this additional US patent for Med 7 is a testament to the company’s dedication to advancing health and well-being by offering cutting-edge, safe, non-pharmaceutical options for conditions that have a dramatic effect on the quality of life,” says Smith in a release. “Med 7 is one of the few hemp-based CBD companies doing clinical research so that consumers of these products know how and where they can be safely used.”
Photo 35738300 © Tomert | Dreamstime.com
Leave a Reply